Photo from wikipedia
Acute myeloid leukaemia (AML) patients who relapse after allogeneic haematopoietic stem cell transplantation (allo-HSCT) have a poor prognosis. The management of AML relapse after allo-HSCT remains a major therapeutic challenge.… Click to show full abstract
Acute myeloid leukaemia (AML) patients who relapse after allogeneic haematopoietic stem cell transplantation (allo-HSCT) have a poor prognosis. The management of AML relapse after allo-HSCT remains a major therapeutic challenge. Here, to the best of our knowledge, we report for the first time a successful treatment based on a programmed death 1 (PD1) inhibitor in combination with 5-azacytidine and low-dose donor lymphocyte infusion (DLI) in two AML patients who relapsed post alloHSCT. Case 1
Journal Title: Bone Marrow Transplantation
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!